Skip to content

Study · Non-randomized trial · n = 10 · 1994

2 results

Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.

Soule S, King JA, Millar RP

The Journal of clinical endocrinology and metabolism1 Oct 1994Cited by 1 (Europe PMC)

PMID7962295 (opens in a new tab)DOI10.1210/jcem.79.4.7962295 (opens in a new tab)PepBankPUB-07962295
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In 10 normal men, the metabolic clearance rate of GHRH-(1-29)-NH2 was higher than that of the D-Ala2 analog.

    In plain wordsIn healthy men, the body cleared GHRH-(1-29)-NH2 faster than the D-Ala2 analog.

    Peptide
    Sermorelin
    Outcome
    IncreaseMetabolic clearance rate
    Study

    n = 10

    Comparator
    D-Ala2-GHRH-(1-29)-NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    25 ng/kg.min · intravenous · 90 minAs given in this study (human).

    Measurements

    Metabolic clearance rate
    39.7 mL/kg.min
    GHRH-(1-29)-NH2

    Source sentences

    Summary
    The MCR of the D-Ala2 analog (mean +/- SE) was significantly less (21 +/- 1.2 mL/kg.min) than that of GHRH-(1-29)-NH2 (39.7 +/- 3.9 mL/kg.min; P < 0.001).
    1 context sentence
    Summary · context
    GHRH-(1-29)-NH2 and D-Ala2-GHRH-(1-29)-NH2 were administered by constant iv infusion at a rate of 25 ng/kg.min to 10 normal men.
  2. 02HumanNon-randomized trialPharmacokinetics

    In 10 normal men, the disappearance half-time of GHRH-(1-29)-NH2 was shorter than that of the D-Ala2 analog.

    In plain wordsIn healthy men, GHRH-(1-29)-NH2 disappeared from the blood faster than the D-Ala2 analog.

    Peptide
    Sermorelin
    Outcome
    DecreaseDisappearance half-time
    Study

    n = 10

    Comparator
    D-Ala2-GHRH-(1-29)-NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    25 ng/kg.min · intravenous · 90 minAs given in this study (human).

    Measurements

    Disappearance half-time
    4.3 min
    GHRH-(1-29)-NH2

    Source sentences

    Summary
    The disappearance half-time of the D-Ala2 analog was 6.7 +/- 0.5, whereas that of GHRH-(1-29)-NH2 was 4.3 +/- 1.4 min (P < 0.05).
    1 context sentence
    Summary · context
    GHRH-(1-29)-NH2 and D-Ala2-GHRH-(1-29)-NH2 were administered by constant iv infusion at a rate of 25 ng/kg.min to 10 normal men.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.